Belite Bio, Inc (BLTE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors & CEO | -- | -- | 1978 |
| Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | CFO & Director | -- | -- | 1984 |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer | -- | -- | 1967 |
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer | -- | -- | 1969 |
Belite Bio, Inc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 25
Description
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Corporate Governance
Upcoming Events
May 14, 2025 at 8:00 PM UTC
Belite Bio, Inc Earnings Date